Tearsheet

Hinge Health (HNGE)


Market Price (6/7/2026): $63.48 | Market Cap: $5.0 BilSector: Health Care | Industry: Health Care Technology

Hinge Health (HNGE)


Market Price (6/7/2026): $63.48
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.

Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%

Weak multi-year price returns
3Y Excs Rtn is -7.3%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -527 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -82%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%

Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.
3 Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%
4 Weak multi-year price returns
3Y Excs Rtn is -7.3%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -527 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -82%
6 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%
9 Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/4/2026

Hinge Health (HNGE) stock has gained about 50% since 2/28/2026 because of the following key factors:

1. Hinge Health reported a significant Q1 2026 earnings beat and raised its full-year guidance.

The company announced an adjusted earnings per share (EPS) of $0.45 for Q1 2026, surpassing the consensus estimate of $0.12 by $0.33. Quarterly revenue increased by 47.2% year-over-year, reaching $182.31 million. Following these strong results, Hinge Health increased its full-year 2026 revenue outlook to between $798 million and $804 million, reflecting 36% year-over-year growth at the midpoint.

2. The company expanded its offerings with new programs like Migraine Care and HingeSelect.

In April 2026, Hinge Health launched its Migraine Care Program, utilizing its FDA-cleared Enso device for drug-free pain relief and personalized trigger management. This program was adopted by over 125 clients, covering more than two million people. Additionally, the introduction of HingeSelect aimed to combine AI-powered exercise therapy with access to in-person providers, broadening the company's integrated care model.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 48.5% change in HNGE stock from 2/28/2026 to 6/6/2026 was primarily driven by a 82.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)22820266062026Change
Stock Price ($)42.7663.4848.5%
Change Contribution By: 
Total Revenues ($ Mil)35564682.2%
P/S Multiple8.37.7-6.6%
Shares Outstanding (Mil)6979-12.8%
Cumulative Contribution48.5%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/6/2026
ReturnCorrelation
HNGE48.8% 
Market (SPY)7.8%31.0%
Sector (XLV)-4.1%21.8%

Fundamental Drivers

The 29.8% change in HNGE stock from 11/30/2025 to 6/6/2026 was primarily driven by a 82.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)113020256062026Change
Stock Price ($)48.9163.4829.8%
Change Contribution By: 
Total Revenues ($ Mil)35564682.2%
P/S Multiple9.57.7-18.3%
Shares Outstanding (Mil)6979-12.8%
Cumulative Contribution29.8%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/6/2026
ReturnCorrelation
HNGE30.1% 
Market (SPY)8.5%25.7%
Sector (XLV)-2.1%10.3%

Fundamental Drivers

The 63.4% change in HNGE stock from 5/31/2025 to 6/6/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)53120256062026Change
Stock Price ($)38.8463.4863.4%
Change Contribution By: 
Total Revenues ($ Mil)6460.0%
P/S Multiple7.70.0%
Shares Outstanding (Mil)6979-12.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/6/2026
ReturnCorrelation
HNGE63.8% 
Market (SPY)26.6%24.1%
Sector (XLV)17.4%3.7%

Fundamental Drivers

null
null

Market Drivers

5/31/2023 to 6/6/2026
ReturnCorrelation
HNGE  
Market (SPY)83.4%24.2%
Sector (XLV)25.8%4.0%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HNGE Return----24%36%68%
Peers Return-46%-65%-39%-63%-28%17%-96%
S&P 500 Return27%-19%24%23%16%11%102%

Monthly Win Rates [3]
HNGE Win Rate----50%67% 
Peers Win Rate31%25%44%33%28%44% 
S&P 500 Win Rate75%42%67%75%67%67% 

Max Drawdowns [4]
HNGE Max Drawdown------37% 
Peers Max Drawdown-74%-69%-71%-76%-74%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/5/2026 (YTD)

How Low Can It Go

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to TDOC, AMWL, DRIO

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to TDOC, AMWL, DRIO

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Hinge Health (HNGE)

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

AI Analysis | Feedback

Livongo for musculoskeletal health

Peloton for medical physical therapy

AI Analysis | Feedback

  • Digital Musculoskeletal (MSK) Care Service: A comprehensive, AI-powered virtual program that provides personalized and largely automated care for joint and muscle health, spanning prevention, acute injury, chronic pain, and post-surgical rehabilitation.
  • TrueMotion AI-powered Motion Tracking Technology: An integrated technology within their service that utilizes AI for real-time exercise feedback and tracks member progress, enabling scalable and personalized therapy.
  • Enso Electrical Nerve Stimulation Wearable Device: A proprietary, FDA-cleared wearable device seamlessly integrated into the service, delivering non-addictive and non-invasive pain relief via electrostimulation.

AI Analysis | Feedback

Hinge Health (HNGE) primarily sells to other companies.

The company's major customers are:

  • Self-insured employers, including many of the nation’s leading enterprises across a broad range of industries and sizes. As of December 31, 2024, Hinge Health had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies.
  • Public sector self-insured employers, such as state and local city governments and labor unions.

While Hinge Health partners with major national health plans and PBMs to facilitate access to clients, and is expanding to serve health plans' fully-insured and Medicare Advantage populations directly, its primary clients are explicitly stated as self-insured employers.

The provided text does not list specific names of the Fortune 100, Fortune 500, or other employer clients. Therefore, specific customer company names and their symbols cannot be provided.

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel Perez, Co-Founder and Chief Executive Officer

Daniel Perez co-founded Hinge Health in 2014. He holds a B.S. in Biology from Westminster University and completed a DPhil (PhD) in Biochemistry from the University of Oxford. Prior to Hinge Health, he co-founded Marblar and the Oxbridge Biotech Roundtable. He was inspired to start Hinge Health with Gabriel Mecklenburg due to their personal experiences with musculoskeletal injuries.

James Budge, Chief Financial Officer

James Budge joined Hinge Health as Chief Financial Officer in March 2023. He brings 25 years of CFO experience across various public and private high-growth technology companies. His previous CFO roles include Automation Anywhere, Pluralsight, Anaplan, Genesys Cloud Services, and Rovi Corporation. Budge has a track record of raising capital, taking companies public, and overseeing numerous acquisitions. He holds a B.S. in Accounting from Brigham Young University. His career has involved accelerating growth for public and late-stage private companies.

Gabriel Mecklenburg, Co-Founder and Executive Chairman

Gabriel Mecklenburg is the Co-Founder and Executive Chairman of Hinge Health, having also served as Chief Operating Officer from October 2014 to February 2021. He co-founded Marblar and Oxbridge Biotech Roundtable Ltd. He holds an M.Sc. in Materials Science from the University of Cambridge and an M. Phil. in Bioengineering from Imperial College London.

Jim Pursley, President

Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer of Livongo Health. He also held various executive positions at Care Innovations and GE HealthCare Technologies. He earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.

Dr. Jeff Krauss, Chief Medical Officer

Dr. Jeff Krauss is the Chief Medical Officer at Hinge Health, a role he assumed in September 2018.

AI Analysis | Feedback

The key risks to Hinge Health's business include:

  1. Challenges with Healthcare Reimbursement and Regulatory Environment: Hinge Health's business model relies on developing "novel billing methods" and partnering with various entities like health plans and pharmacy benefit managers (PBMs) to navigate the complex healthcare reimbursement framework. The healthcare industry is heavily regulated, and any changes to reimbursement policies, challenges in gaining acceptance for their billing methods, or difficulties in expanding into new, highly regulated segments like fully-insured and Medicare Advantage populations and federal insurance plans, could significantly impact their revenue and growth trajectory.
  2. Dependence on AI-Powered Technology Efficacy and Member Engagement: Hinge Health's core value proposition is built on its AI-powered motion tracking technology (TrueMotion) and proprietary FDA-cleared wearable device (Enso), which largely automate care for joint and muscle health and aim to reduce human care team hours by approximately 95%. A significant risk lies in the continuous efficacy of these technologies in delivering superior clinical outcomes, maintaining high member satisfaction, and sustaining member engagement, particularly given the inherent difficulty of automating unstructured physical tasks in healthcare. Any technical failures, lack of desired clinical results, or a decline in member trust and adoption could undermine the company's value proposition.
  3. Intense Competition and Market Penetration Challenges: While Hinge Health operates in a "massive" musculoskeletal (MSK) market, the healthcare industry has "no shortage of new technologies," implying a highly competitive landscape. Despite significant client retention rates and contracts with a large percentage of Fortune 100 and 500 companies, Hinge Health's current contracted lives represent only 5% of its total addressable market. The company faces the ongoing challenge of effectively competing with existing solutions and new market entrants, and efficiently penetrating the remaining 95% of the market to sustain its growth.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for Hinge Health's main products and services, which include its digital musculoskeletal (MSK) care platform, is approximately 400 million lives in the U.S.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Hinge Health (HNGE)

Hinge Health anticipates several key drivers for its revenue growth over the next 2-3 years, primarily stemming from its extensive market opportunity, strategic partnerships, and expansion into new customer segments.
  1. Growth in contracted lives and client acquisition: Hinge Health currently serves approximately 20 million contracted lives, which represents only 5% of its total addressable market. This leaves substantial room for growth through acquiring new self-insured employers and increasing penetration within the Fortune 100 and Fortune 500 companies, where it already has significant presence but still opportunities to expand.
  2. Expansion into new market segments: The company is in the early stages of broadening its reach beyond self-insured employers to serve fully-insured and Medicare Advantage populations of health plans, as well as federal insurance plans. This strategic expansion into new payer types opens up large, previously untapped revenue streams.
  3. Deepening engagement and penetration within existing client base: Hinge Health benefits from a recurring revenue model, demonstrated by a net dollar retention of 117% as of December 31, 2024, and a 12-month client retention rate of 98%. This indicates a strong ability to enroll, engage, and re-engage eligible members within its existing client contracts, leading to organic revenue growth over the typical three-year contract term.
  4. Leveraging and expanding its partner network: With over 50 partners, including the five largest national health plans and top three PBMs, Hinge Health's partner network is a crucial component of its efficient go-to-market strategy. These partnerships reduce friction in contracting, procurement, and onboarding, facilitating the efficient provision of its platform to clients and members, thereby accelerating client acquisition and growth in contracted lives.

AI Analysis | Feedback

null

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Price63.627.058.627.508.06
Mkt Cap5.00.00.10.10.1
Rev LTM6462,51423722442
Op Inc LTM-527-157-92-37-125
FCF LTM203127-45-2650
FCF 3Y Avg-169-113-32-32
CFO LTM210288-42-2692
CFO 3Y Avg-311-104-32-32

Growth & Margins

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Rev Chg LTM49.8%-1.5%-9.3%-17.3%-5.4%
Rev Chg 3Y Avg-0.7%-4.9%-3.6%-3.6%
Rev Chg Q47.2%-2.5%-17.9%-31.2%-10.2%
QoQ Delta Rev Chg LTM9.9%-0.6%-4.8%-9.6%-2.7%
Op Inc Chg LTM-4,269.1%15.8%46.6%36.5%26.2%
Op Inc Chg 3Y Avg-11.0%28.1%11.6%11.6%
Op Mgn LTM-81.6%-6.3%-38.9%-163.9%-60.2%
Op Mgn 3Y Avg-39.0%-7.4%-69.5%-217.9%-54.3%
QoQ Delta Op Mgn LTM11.3%0.2%3.3%-3.2%1.8%
CFO/Rev LTM32.4%11.5%-17.6%-116.0%-3.1%
CFO/Rev 3Y Avg-12.1%-41.1%-136.0%-41.1%
FCF/Rev LTM31.4%5.0%-18.8%-116.7%-6.9%
FCF/Rev 3Y Avg-6.6%-44.6%-137.3%-44.6%

Valuation

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Cap5.00.00.10.10.1
P/S7.70.00.62.31.5
P/Op Inc-9.5-0.3-1.5-1.4-1.5
P/EBIT-9.5-0.3-1.5-1.4-1.5
P/E-9.8-0.2-1.6-1.2-1.4
P/CFO23.90.1-3.4-2.0-0.9
Total Yield-10.2%-406.6%-61.5%-80.5%-71.0%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-338.8%-72.2%-1,580.3%-72.2%
D/E0.024.70.00.60.3
Net D/E-0.16.8-1.20.10.0

Returns

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
1M Rtn15.7%1.3%11.2%-7.7%6.3%
3M Rtn37.9%38.8%57.9%-22.7%38.3%
6M Rtn27.1%-7.1%115.0%-36.7%10.0%
12M Rtn63.6%-3.0%23.9%-46.5%10.4%
3Y Rtn69.4%-71.9%-83.7%-90.9%-77.8%
1M Excs Rtn15.8%3.4%20.3%-6.3%9.6%
3M Excs Rtn28.3%29.2%48.3%-32.2%28.8%
6M Excs Rtn30.4%-14.2%103.5%-44.5%8.1%
12M Excs Rtn35.3%-24.6%0.9%-69.8%-11.9%
3Y Excs Rtn-7.3%-146.2%-157.1%-167.0%-151.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024
Single Segment390293
Total390293


Net Income by Segment
$ Mil20252024
Single Segment-12-108
Total-12-108


Price Behavior

Price Behavior
Market Price$63.62 
Market Cap ($ Bil)5.0 
First Trading Date05/22/2025 
Distance from 52W High0.0% 
   50 Days200 Days
DMA Price$39.47$40.65
DMA Trendupup
Distance from DMA61.2%56.5%
 3M1YR
Volatility54.1%64.3%
Downside Capture53.26143.93
Upside Capture153.24165.82
Correlation (SPY)33.6%24.9%
HNGE Betas & Captures as of 5/31/2026

 1M2M3M6M1Y3Y
Beta0.530.831.221.221.340.30
Up Beta4.841.621.180.721.45-0.17
Down Beta-0.02-1.141.851.820.51-0.25
Up Capture148%164%150%132%211%19%
Bmk +ve Days13283667141432
Stock +ve Days15293968129131
Down Capture-447%-162%66%119%140%69%
Bmk -ve Days7132757109318
Stock -ve Days5122456117120

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE65.0%64.1%1.03-
Sector ETF (XLV)16.9%15.0%0.833.4%
Equity (SPY)25.3%12.1%1.5723.8%
Gold (GLD)27.6%26.9%0.88-0.5%
Commodities (DBC)36.9%19.0%1.52-6.5%
Real Estate (VNQ)12.5%13.3%0.638.8%
Bitcoin (BTCUSD)-42.0%42.5%-1.1611.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE11.9%64.0%1.10-
Sector ETF (XLV)6.1%14.7%0.233.6%
Equity (SPY)13.5%17.1%0.6223.9%
Gold (GLD)17.3%18.1%0.780.4%
Commodities (DBC)9.5%19.4%0.38-5.4%
Real Estate (VNQ)3.2%18.8%0.079.2%
Bitcoin (BTCUSD)11.3%54.6%0.4011.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE5.8%64.0%1.10-
Sector ETF (XLV)9.9%16.6%0.483.6%
Equity (SPY)15.3%17.9%0.7323.9%
Gold (GLD)13.0%16.0%0.670.4%
Commodities (DBC)7.1%18.0%0.32-5.4%
Real Estate (VNQ)5.6%20.7%0.249.2%
Bitcoin (BTCUSD)63.3%66.9%1.0311.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date5152026
Short Interest: Shares Quantity4.2 Mil
Short Interest: % Change Since 43020262.5%
Average Daily Volume2.3 Mil
Days-to-Cover Short Interest1.8 days
Basic Shares Quantity78.6 Mil
Short % of Basic Shares5.4%

Earnings Returns History

Updated 6/7/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/5/202610.2%11.0%26.6%
2/10/202617.3%22.7%34.5%
11/4/2025-15.1%-17.1%-6.4%
8/5/202525.6%16.1%16.2%
SUMMARY STATS   
# Positive333
# Negative111
Median Positive17.3%16.1%26.6%
Median Negative-15.1%-17.1%-6.4%
Max Positive25.6%22.7%34.5%
Max Negative-15.1%-17.1%-6.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202503/03/202610-K
09/30/202511/07/202510-Q
06/30/202508/11/202510-Q
03/31/202505/23/2025424B4

Recent Forward Guidance

Updated 6/1/2026

Latest: Q1 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Revenue194.00 Mil195.00 Mil196.00 Mil   
Q2 2026 Non-GAAP Income from Operations47.00 Mil48.00 Mil49.00 Mil   
Q2 2026 Non-GAAP Operating Margin 25.0%    
2026 Revenue798.00 Mil801.00 Mil804.00 Mil8.7% RaisedGuidance: 737.00 Mil for 2026
2026 Non-GAAP Income from Operations205.00 Mil210.00 Mil215.00 Mil36.8% RaisedGuidance: 153.50 Mil for 2026
2026 Non-GAAP Operating Margin 26.0% 23.8%5.0%RaisedGuidance: 21.0% for 2026

Prior: Q4 2025 Earnings Reported 2/10/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue171.00 Mil172.00 Mil173.00 Mil10.3% Higher NewGuidance: 156.00 Mil for Q4 2025
Q1 2026 Non-GAAP Income from Operations30.00 Mil31.00 Mil32.00 Mil-11.4% Lower NewGuidance: 35.00 Mil for Q4 2025
Q1 2026 Non-GAAP Operating Margin 18.0%    
2026 Revenue732.00 Mil737.00 Mil742.00 Mil28.6% Higher NewGuidance: 573.00 Mil for 2025
2026 Non-GAAP Income from Operations151.00 Mil153.50 Mil156.00 Mil43.5% Higher NewGuidance: 107.00 Mil for 2025
2026 Non-GAAP Operating Margin 21.0%    

Insider Activity

Updated 6/7/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Mecklenburg, Gabriel MIDirectSell605202665.5450,000  Form
2Robinson, Elliott See footnoteSell60320260.000  Form
3Robinson, Elliott See footnoteSell60320260.000  Form
4Mecklenburg, Gabriel MIDirectSell603202660.2283,334  Form
5Pursley, JamesPresidentDirectSell527202653.7916,000860,60641,966,523Form
Core Cache Last Updated: 6/6/2026